Low-dose fondaparinux in suspected heparin-induced thrombocytopenia in the critically ill

Netherlands Journal of Medicine

Volumn 65, Issue 3, 2007, Pages 101-108

  Wester, J P J ^a   Leyte, A ^a   Oudemans van Straaten, H M ^a   Bosman, R J ^a   Van der Spoel, J I ^a   Haak, E A F ^a   Porcelijn, L ^b   Zandstra, D F ^a  

^a Onze Lieve Vrouwe Gasthuis ^*  (Netherlands)

^b CENTRAL LABORATORY   (Netherlands)

Author keywords

Critically ill; Fondaparinux sodium; Heparin induced thrombocytopenia; Pentasaccharide

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; CITRATE TRISODIUM; CREATININE; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; NADROPARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD ANALYSIS; CLINICAL ARTICLE; COHORT ANALYSIS; CONTINUOUS HEMOFILTRATION; CONTINUOUS INFUSION; CORRELATION ANALYSIS; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG WITHDRAWAL; ERYTHROCYTE TRANSFUSION; FEMALE; HEPARIN INDUCED THROMBOCYTOPENIA; HUMAN; INTENSIVE CARE UNIT; LOW DRUG DOSE; MALE; PROTHROMBIN TIME; RETROSPECTIVE STUDY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; THROMBOSIS; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CHEMOPREVENTION; CRITICAL CARE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HEPARIN; HOSPITALS, TEACHING; HUMANS; INTENSIVE CARE UNITS; MALE; MIDDLE AGED; POLYSACCHARIDES; RETROSPECTIVE STUDIES; THROMBOCYTOPENIA;

EID: 33947651116     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Wester JPJ, Leyte A, Porcelijn L, et al. The diagnosis and the estimated incidence of heparin-induced thrombocytopenia in the critically ill according to the ISTH SSC criteria (abstract). J Thromb Haemost 2005;3(Supplement 1):P0314.
2. Warkentin TE, Cook DJ. Heparin, low molecular weight heparin, and heparin-induced thrombocytopenia in the ICU. Crit Cate Clin 2005;21:513-29.
3. Chong BH, Chong JJH. Heparin-induced thrombocytopenia. Expert Rev Cardiovasc Ther 2004;2:547-59.
4. Warkentin TE. Heparin-induced thrombocytopenia. Diagnosis and management. Circulation 2004;110:e454-8.
5. Magnani HN. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993;70:554-61.
6. Lubenow N, Eichler P, Lietz T, Greinacher A, for the HIT Investigators Group. Lepirudin in patients with heparin-induced thrombocytopenia - results of the third prospective study (HAT-3) and a combined analysis of HAT-1, HAT-2, and HAT-3. J Thromb Haemost 2005;3:2428-36.
7. Wester JPJ, ten Cate J, Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Zandstra DF. Lepirudin anticoagulation in critically ill patients with (suspected) heparin-induced thrombocytopenia and thrombosis (abstract). J Thromb Haemost 2003;1(Suppl 1):P1907.
8. Kodityal S, Nguyen PH, Kodityal A, Shere J, Hursting MJ, Rice L. Argatroban for suspected heparin-induced thrombocytopenia: contemporary experience at a large teaching hospital. J Intensive Care Med 2006;21:86-92.
9. Williamson DR, Boulanger I, Tardif M, Albert M, Gregoire G. Argatroban dosing in intensive cate patients with acute renal failure and liver dysfunction. Pharmacotherapy 2004;24:409-14.
10. Bauer KA, Hawkins DW, Peters PC, et al. Fondaparinux, a synthetic pentasaccharide: the first in a new class of antithrombotic agents the selective factor Xa inhibitors. Cardiovascular Drug Review 2002;20:37-52.
11. Faaij RA, Burggraaf J, Schoemaker HC, Stiekema J, Siegert C, Cohen AF. The influence of renal function on the pharmacokinetics (PK) and pharmacodynamics of the novel antithrombotic agent Org31540/SR90107A (abstract). Br J Clin Pharmacol 1998;45:211P-2P.
12. Savi P, Chong BH, Greinacher A, et al. Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood 2005;105:139-44.
13. Warkentin TE, Cook RJ, Marder VJ, et al. Anti-platelet factor 4/heparin antibodies in orthopedic surgery patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood 2005;106:3791-6.
14. Bijsterveld NR, Moons AH, Boekholdt SM, et al. Ability of recombinant factor VIIa to reverse the anticoagulant effect of the pentasaccharide fondaparinux in healthy volunteers. Circulation 2002;106:2550-4.
15. D'Amico E, Villaça PR, Gualandro SFM, Bassitt RP, Chamone DAF. Successful use of Arixtra® in a patient with paroxysmal nocturnal hemoglobinuria, Budd-Chiari syndrome and heparin-induced thrombocytopenia. J Thromb Haemost 2003;1:2452-3.
16. Parody R, Oliver A, Souto JC, Fontcuberta J. Fondaparinux (Arixtra®), as an alternative anti-thrombotic prophylaxis when there is hypersensitivity to low molecular weight and unfractionated heparins. Haematologica 2003;88:(11) ECR32.
17. Harenberg J, Jörg I, Fenyvesi T. Treatment of heparin-induced thrombocytopenia with fondaparinux. Haematologica 2004;89:1017-8.
18. Kuo KHM, Kovacs MJ. Successful treatment of heparin induced thrombocytopenia (HIT) with fondaparinux. Thromb Haemost 2005;93:999-1000.
19. Sideris SK, Bonios MJ, Eftihiadis EE, et al. Severe thrombocytopenia after heparin therapy in a patient with unstable angina and recent stent implantation. Hellenic J Cardiol 2005;46:242-6.
20. Haase M, Bellomo R, Rocktaeschel J, et al. Use of fondaparinux (ARIXTRA) in a dialysis patient with symptomatic heparin-induced thrombocytopaenia type II. Nephrol Dial Transplant 2005;20:444-6.
21. Oudemans-van Straaten HM, Bosman RJ, van der Spoel JI, Zandstra DF. Outcome of critically ill patients treated with intermittent high-volume haemofiltration: a prospective cohort analysis. Intensive Care Med 1999;25:814-21.
22. Oudemans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC. Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 2006;32:188-202.
23. Lo GK, Juhl D, Warkentin TE, Sigouin CS, Eichler P, Greinacher A. Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinica) settings. J Thromb Haemost 2006;4:759-65.
24. Landefeld CS, Anderson PA, Goodnough LT, et al. The bleeding severity index: validation and comparison to other methods for classifying bleeding complications of medical therapy. J Clin Epidemiol 1989;42:711-8.
25. Hebert PC, Wells G, Blajchman MA, et al. and the Transfusion Requirements in Critical Care Investigators for the Canadian Critical Care Trials Group. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999;340:409-17.
26. Hebert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29:227-34.
27. Dean AD, Dean JA, Burton AH, Dicker AC. Epi Info, Version 5: a word processing, database, and statistics program for epidemiology on micro-computers. USD, Incorporated, Stone Mountain, Georgia, 1990.
28. Glantz SA. Primer of biostatistics: the program (version 3.0). McGraw-Hill, Inc. 1990.
29. Taylor Jr FB, Toh C-H, Hoots WK, Wada H, Levi M, on behalf of the Scientific Subcommittee on Disseminated Intravascular Coagulation (DIC) of the International Society on Thrombosis and Haemostasis (ISTH). Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
30. Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med 1998;105:27-32.
31. Mulder J, Tan HK, Bellomo R, Silvester W. Platelet loss across the hemofilter during continuous hemofiltration. Int J Artif Organs 2003;26:906-12.